A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Recurrent Glioblastoma
Latest Information Update: 31 Oct 2024
Price :
$35 *
At a glance
- Drugs BL-B01D1 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
- 28 Oct 2024 Status changed from not yet recruiting to recruiting.
- 27 Sep 2024 New trial record